Prioritize PADO products in research and development plans
Pharmaceutical companies

Prioritize PADO products in research and development plans

Pharmaceutical companies

ViiV has committed additional resources in Pediatrics with the appointment of a Head of Pediatric Strategy (Bill Collier) who has convened a cross-functional team to address possible ways to accelerate development of DTG for pediatrics.

-

Review ARV portfolio, prioritize PADO products and communicate changes with stakeholders by IAC July 2018.

-

-

-

Demonstrate timely implementation of PADO priorities as part of their paediatric portfolio (by 2020).

-

-

-

-

-

-

-

Sub-Actions & Milestones

Updates

Notes

Responsible